Arcutis Survey Highlights Gaps in Chronic Skin Disease Management
Event summary
- Arcutis Biotherapeutics released a nationwide survey showing 88% of adults and 91% of parents concerned about topical steroid side effects.
- 72% of adults and 80% of children with chronic skin conditions experience uncontrolled disease at least monthly.
- Nearly 8 in 10 respondents report treatment plans focus on reactive flare management rather than proactive long-term strategies.
- Survey conducted among 1,500 participants (1,000 adults, 500 parents) with plaque psoriasis, eczema, or seborrheic dermatitis.
The big picture
The survey underscores a systemic gap in chronic skin disease management, where reactive flare treatment dominates despite patient concerns about steroid side effects. This aligns with broader industry trends toward personalized medicine and proactive disease management strategies. Arcutis positions itself to capitalize on this shift with its portfolio of targeted topical therapies.
What we're watching
- Treatment Innovation
- How Arcutis will leverage these findings to accelerate development of non-steroidal alternatives.
- Market Opportunity
- Whether the survey results can shift payer and prescriber attitudes toward proactive disease management.
- Regulatory Dynamics
- The pace at which regulators may support approval pathways for long-term, non-steroidal treatment options.